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An Uncommon Complication of a Common Medication:  
Diffuse Alveolar Hemorrhage Secondary to Supratherapeutic INR 
Nathan Brewster DO1, Chris Lenivy DO1, Kareem Godil MD1, Andres Zirlinger MD2 
1Department of Internal Medicine; 2Division of Pulmonary and Critical Care Medicine, Lehigh Valley Health Network, Allentown, Pa.
INTRODUCTION
Diffuse alveolar hemorrhage (DAH) is an uncommon cause of acute 
hypoxic respiratory failure. The many etiologies for DAH include 
infection, connective tissue disease, vasculitis, and inhalational injury. 
DAH secondary to a supratherapeutic INR is a known but rare 
complication of warfarin which is only reported in a paucity of case 
reports.1-5 High index of suspicion is necessary in order to diagnose 
DAH in this rare instance. 
CASE DESCRIPTION
A 73-year-old female with COPD, diastolic CHF, end stage renal 
disease, and atrial fibrillation presented to the hospital in respiratory 
distress. On exam, she was hypoxic with an oxygen saturation of  
80% on ambient air. She acknowledged non-compliance with a fluid 
restrictive diet. A chest x-ray showed diffuse pulmonary infiltrates with 
no pleural effusions (Image 1) initially interpreted as pulmonary edema. 
The patient was emergently hemo-dialyzed removing two liters of  
fluid and placed on BiPAP without improvement. Due to persistent 
respiratory distress, she was ultimately intubated. A CT scan of the 
chest revealed diffuse ground-glass opacities and no interlobular 
septal thickening to suggest interstitial edema (Image 2). Based on 
these findings, a bronchoscopy was done with three subsequent 
bronchoalveolar lavages (BAL) consistent with DAH. Her initial INR 
was 9.5 and Vitamin K was administered for reversal of warfarin. 
Serologies for vasculitides and connective tissue disease including ANA, 
ANCA, C3 and C4, cryoglobulins, anti-GBM, and RF were normal. 
The BAL viral panel and bacterial cultures were also negative. DAH 
was attributed to the supratherapeutic INR. After reversing the INR, 
the patient began to improve and was eventually discharged home. 
DISCUSSION
DAH can be a diagnostic challenge. It requires a high 
degree of clinical suspicion in patients presenting with  
a supratherapeutic INR and respiratory distress. DAH 
must remain on the differential for patients on warfarin  
in respiratory distress and bilateral infiltrates on x-ray, 
particularly when heart failure is a comorbidity, as high 
pulmonary vascular pressures can facilitate alveolar 
hemorrhage. Treatment for DAH related to anticoagulation 
is reversal of coagulopathy with vitamin K, and, if needed, 
prothrombin complex concentrate or fresh frozen plasma. 
We have found no specific recommendations regarding 
the timing of reinitiation of anticoagulation. 
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Image 1. Chest x-ray showing pulmonary vascular congestion as well as 
interstitial edema.
Image 2. CT of the chest showing bilateral alveolar ground-glass opacities 
involving he upper lobes as well as the right middle and left lower lobes.
